Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Combination of Iguratimod and Danazol Versus Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial

NCT05281068 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05281068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05281068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Combination of Iguratimod and Danazol Versus Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: A Randomized, Controlled, Multicenter, Open-label Trial
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
December 30, 2023
Enrollment
120 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia, itp